Advancing Access
to the Biology of the Brain

The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, will transform the way brain injuries and diseases are diagnosed.

Simoa assays can detect biomarkers associated with brain injury and disease at much earlier stages to understand the long-term effects and disease pathology. Quanterix has a strategic focus in neurology and neurodegeneration and is working with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research.

Latest News

As a company that believes we have the power to improve player safety, we also know that change cannot happen unless we have unified support from the entire community, including researchers, scientists, doctors, patients, patient advocates, investors, and institutions like the NFL.
A new ecosystem of portable technologies has the potential to enhance our ability to treat and mitigate the effects of head trauma.

Request to Learn More